| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 呼吸系统药物(元) | 299,141,566.90 | 988,921,792.03 | 653,367,876.12 |
| 其它药物(元) | 28,793,974.06 | 97,623,632.56 | 47,382,778.90 |
| 全身用抗感染药物(元) | 49,511,770.43 | 128,844,476.14 | 73,076,022.09 |
| 消化系统药物(元) | 108,781,043.48 | 146,062,822.29 | 90,529,967.27 |
| 原料药(元) | 21,442,557.55 | 52,095,629.02 | 24,592,806.91 |
| 营业成本(元) | |||
| 呼吸系统药物(元) | 175,791,749.76 | 509,301,219.68 | 321,343,226.55 |
| 其它药物(元) | 18,823,113.61 | 52,711,573.71 | 20,418,647.62 |
| 全身用抗感染药物(元) | 37,468,437.88 | 86,257,182.94 | 44,293,012.18 |
| 消化系统药物(元) | 44,091,556.57 | 61,458,889.85 | 32,480,584.39 |
| 原料药(元) | 11,792,441.33 | 27,376,716.29 | 14,042,347.70 |
| 毛利(元) | |||
| 呼吸系统药物(元) | 123,349,817.14 | 479,620,572.35 | 332,024,649.57 |
| 其它药物(元) | 9,970,860.45 | 44,912,058.85 | 26,964,131.28 |
| 全身用抗感染药物(元) | 12,043,332.55 | 42,587,293.20 | 28,783,009.91 |
| 消化系统药物(元) | 64,689,486.91 | 84,603,932.44 | 58,049,382.88 |
| 原料药(元) | 9,650,116.22 | 24,718,912.73 | 10,550,459.21 |
| 毛利率(%) | |||
| 呼吸系统药物(%) | 41.23 | 48.50 | 50.82 |
| 其它药物(%) | 34.63 | 46.01 | 56.91 |
| 全身用抗感染药物(%) | 24.32 | 33.05 | 39.39 |
| 消化系统药物(%) | 59.47 | 57.92 | 64.12 |
| 原料药(%) | 45.00 | 47.45 | 42.90 |
| 收入构成(%) | |||
| 呼吸系统药物(%) | 58.92 | 69.96 | 73.50 |
| 其它药物(%) | 5.67 | 6.91 | 5.33 |
| 全身用抗感染药物(%) | 9.75 | 9.11 | 8.22 |
| 消化系统药物(%) | 21.43 | 10.33 | 10.18 |
| 原料药(%) | 4.22 | 3.69 | 2.77 |
| 毛利构成(%) | |||
| 呼吸系统药物(%) | 56.14 | 70.90 | 72.75 |
| 其它药物(%) | 4.54 | 6.64 | 5.91 |
| 全身用抗感染药物(%) | 5.48 | 6.30 | 6.31 |
| 消化系统药物(%) | 29.44 | 12.51 | 12.72 |
| 原料药(%) | 4.39 | 3.65 | 2.31 |